Adaptive Biotechnologies Corp (Symbol: ADPT) has seen its stock price rise to $11.98 per share, surpassing the average 12-month target price set by analysts at $11.62. This price point has prompted analysts to reassess their positions, with potential moves to either downgrade on valuation or increase their target prices based on the company’s performance.
As of now, eight analysts contribute to the average target, with prices ranging from $9.00 to $15.00 and a standard deviation of $1.995. Current analyst ratings indicate eight “Strong Buy” recommendations, one “Hold,” and no sell ratings, maintaining an average rating of 1.22 on a scale of 1 to 5 (where 1 is Strong Buy and 5 is Strong Sell).
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
